UAB - Center for Clinical and Translational Science

Imaging With [89Zr]Panitumumab-PET/MRI in Patients With Newly Diagnosed Colorectal Cancer

Purpose

This clinical study will investigate the utility of PET imaging with [89Zr]Panitumumab for imaging of EGFR expression in newly diagnosed colon cancer patients to assess lymph node involvement. If promising, this data will be used to design larger trials.

Condition

Metastatic Colon Cancer

Eligibility

Eligible Ages: Over 19 Years
Eligible Genders: All
Accepts Healthy Volunteers: No

Inclusion Criteria

Be at least 19 years of age. - Diagnosis of colon cancer - Scheduled to undergo surgical resection

Exclusion Criteria

Inability to provide informed consent - Pregnancy - Inability to lie still for the imaging study - Weight over 350 lbs., due to the scanner bore size - Contraindication for MRI study (e.g. non-removable metal implants or certain tattoos) - Inability to receive Omnipaque (iohexol) iodinated contrast - Inability to receive glucagon - Inability to receive Eovist (gadoxetate disodium) gadolinium based contrast agent - Allergy to contrast imaging agents - Finding or suspicion of distant metastases on CT

Study Design

Phase: Phase 1/Phase 2
Study Type: Interventional
Allocation: N/A
Intervention Model: Single Group Assignment
Primary Purpose: Diagnostic
Masking: None (Open Label)

Arm Groups

Arm	Description	Assigned Intervention
Experimental [89Zr]Panitumumab-PET/MRI patients	All study patients will receive [89Zr]Panitumumab-PET/MRI imaging.	Drug: [89Zr]Panitumumab PET-MRI All patients entered into the study will have [89Zr]Panitumumab-PET/MRI imaging.

More Details

Status: Withdrawn
Sponsor: University of Alabama at Birmingham

Study Contact

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.